Table 1.
Characteristic | Intravenous CYP | MEPEX |
---|---|---|
Number of patients | 41 | 37 |
Age (yr), median (range) | 62 (19–98) | 64 (28–80) |
ANCA type, n | ||
MPO | 20 | 19 |
PR3 | 19 | 12 |
ANCA negative | 1 | 6 |
MPO and PR3 | 1 | |
Pulmonary hemorrhage, n (%) | 13 (32) | 7 (19) |
Extrarenal involvement, n (%) | 18 (44) | 24 (65) |
CYP, cyclophosphamide; MPO, myeloperoxidase; PR3, proteinase 3; MEPEX, methylprednisolone versus plasma exchange (oral cyclophosphamide cohort).